This article is more than 5 years old. Information may no longer be current.

EyeGate’s iontophoretic delivery of corticosteroids gets US patent

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The United States Patent and Trademark Office has granted EyeGate Pharmaceuticals a patent for its iontophoresis delivery of corticosteroids to the eye, according to a company press release.

EGP-437, EyeGate’s product candidate, is a formulation of iontophoretically delivered dexamethasone phosphate. It is currently in a phase 3 study in uveitis and a phase 2b study to treat pain and inflammation after cataract surgery.

A subsidiary of Valeant Pharmaceuticals has a license for EGP-437 for both of these indications.